Genfit - ADR

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Earnings data Q2 2024

Laboratory

GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

Lille, France; Cambridge, M.A.; September 24, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the first patient first visit for ELATIVE, the global, pivotal, Phase 3 study evaluating elafibranor in Primary Biliary Cholangitis (PBC).

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Lille, France; Cambridge, M.A.; September 22, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, will announce its first half-year 2020 financial results and new corporate strategy following market close on Wednesday, September 30, 2020.

GENFIT To Announce First Half-Year 2020 Financial Results and New Corporate Strategy on September 30, 2020

Lille, France; Cambridge, M.A.; August 26, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced two oral presentations on new non-alcoholic steatohepatitis (NASH) data, at the Digital International Liver Congress™ 2020, the 55th Annual Meeting of the European Association for the Study of the Liver (EASL), to be held virtually August 27-29, 2020.

GENFIT Announces Two Oral Presentations at the Digital International Liver Congress™ 2020

Lille (France), Cambridge (Massachusetts, United States), August 05, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced that pivotal data describing the derivation and validation of NIS4™ has been accepted for publication by   The Lancet Gastroenterology & Hepatology  . NIS4™ is GENFIT’s novel non-invasive, blood-based diagnostic technology, developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F> 2), also referred to as at-risk NASH in the published study.  

GENFIT Announces Pivotal Publication of NIS4™ Technology to Identify Patients with At-Risk NASH in The Lancet Gastroenterology & Hepatology

GENFIT: Provides Initial Update on Corporate Strategy

Genfit: Beaten Down But Not Dead

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Genfit (GNFT) Stock a Solid Choice Right Now

Genfit’s (NASDAQ:GNFT) loss may be a gain for other companies developing a treatment for one of the most rapidly growing health problems around the world, particularly Intercept Pharmaceuticals Inc.

After Drug Failure, Genfit's Cupboard Is Nearly Bare

CymaBay Therapeutics

Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge.

Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage Study

One of the company's pipeline candidates flopped in a late-stage clinical trial.

Why Genfit Is Cratering Today

Genfit stock lost half its value late Monday after the biotech company's promising hepatitis treatment failed in a Phase 3 test. The results are a boon for rival Intercept Pharmaceuticals.

This Biotech Just Lost Half Its Value After A Key Hepatitis Drug Failed

Why Genfit (GNFT) Stock Might be a Great Pick

Bristol-Myers

Intercept Pharma

Madrigal Pharmaceuticals

Novartis

PTC Therapeutics

Roche Holding AG

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Intercept Pharmaceuticals Inc.

FDA Decisions on 5 Drugs Expected in 2nd Quarter

Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches

As of late, it has definitely been a great time to be an investor in Genfit.

Will Genfit Continue to Surge Higher?

A French biopharmaceutical company hopes to become the first to gain approval of a drug to treat a widespread liver disease.

Genfit Hopes to Buck the Odds With NASH Drug

Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?

Better Buy: Intercept Pharmaceuticals or Genfit?

Genfit (NASDAQ: GNFT) on Monday afternoon announced a partnership with Terns Pharmaceuticals to develop and commercialize Elafibranor in Greater China.

Genfit Partners With Terns Pharma To Develop, Commercialize Elafibranor In China

Genfit expects to report interim results from its phase 3 NASH study, which is expected to be read out by the end of 2019.

Genfit Is Gearing Up For A Major Catalyst In NASH Before The End Of 2019

Genfit received Breakthrough Therapy Designation from the FDA for its Elafibranor to treat patients with primary biliary cholangitis.

Genfit Breakthrough Therapy Designation Based On Impressive Data

Cara Therapeutics

Editas Medicine

They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.

News for Genfit - ADR Stock (GNFT)